Phase 2
Completed N=21
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Source: ClinicalTrials.gov NCT05052723 ↗Enrolled (actual)
21
Serious AEs
61.9%
Results posted
Nov 2025
Primary outcomePrimary: Progression-free Survival — 2 Participants
Summary
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
2 | — |
| SECONDARY Number of Participants With Response to Therapy |
1 | — |
| SECONDARY Number of Participants With Complete Response |
— | — |
| SECONDARY Number of Participants With Partial Response |
1 | — |
| SECONDARY Overall Participant Survival Rate |
2 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of pancreatic ductal adenocarcinoma
- Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
- Patients must have adequate organ function
Exclusion Criteria
- Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
- Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
- Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
- Clinically significant cardiovascular disease
- Uncontrolled hypertension
- Inability to swallow tablets
Data sourced from ClinicalTrials.gov (NCT05052723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.